Research Analysts’ Weekly Ratings Updates for Terns Pharmaceuticals (TERN)

Several analysts have recently updated their ratings and price targets for Terns Pharmaceuticals (NASDAQ: TERN):

• 12/1/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Terns Pharmaceuticals was given a new $33.00 price target on by analysts at Mizuho.
• 11/26/2025 – Terns Pharmaceuticals was given a new $35.00 price target on by analysts at JMP Securities.
• 11/26/2025 – Terns Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/26/2025 – Terns Pharmaceuticals had its price target raised by analysts at Citizens Jmp from $25.00 to $35.00. They now have a “market outperform” rating on the stock.
• 11/25/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $28.00 to $36.00. They now have an “overweight” rating on the stock.
• 11/24/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Terns Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $28.00 to $35.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Terns Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $22.00 to $30.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – Terns Pharmaceuticals had its price target raised by analysts at Mizuho from $32.00 to $33.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $27.00 to $28.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $28.00 price target on the stock, up previously from $20.00.
• 11/4/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $14.00 to $27.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals had its price target raised by analysts at Mizuho from $9.00 to $32.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating. They now have a $20.00 price target on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $15.00 to $22.00. They now have an “outperform” rating on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $24.00 price target on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $28.00 to $35.00. They now have a “buy” rating on the stock.
• 11/3/2025 – Terns Pharmaceuticals was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
• 10/25/2025 – Terns Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 10/23/2025 – Terns Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/23/2025 – Terns Pharmaceuticals had its price target lowered by analysts at JMP Securities from $20.00 to $15.00. They now have a “market outperform” rating on the stock.
• 10/22/2025 – Terns Pharmaceuticals was given a new $9.00 price target on by analysts at Mizuho.
• 10/22/2025 – Terns Pharmaceuticals was given a new $17.00 price target on by analysts at Oppenheimer Holdings, Inc..
• 10/22/2025 – Terns Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $15.00 to $14.00. They now have an “overweight” rating on the stock.
• 10/14/2025 – Terns Pharmaceuticals is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $20.00 price target on the stock.
• 10/8/2025 – Terns Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, Director Jill M. Quigley sold 24,520 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.